Snyder Capital Management L P Raises Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Snyder Capital Management L P raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,168,453 shares of the biopharmaceutical company's stock after purchasing an additional 105,086 shares during the period. Halozyme Therapeutics comprises about 4.2% of Snyder Capital Management L P's portfolio, making the stock its 4th largest holding. Snyder Capital Management L P owned approximately 3.28% of Halozyme Therapeutics worth $199,294,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in Halozyme Therapeutics in the third quarter worth about $434,000. World Investment Advisors LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $3,293,000. Tidal Investments LLC boosted its stake in Halozyme Therapeutics by 265.5% in the 3rd quarter. Tidal Investments LLC now owns 20,576 shares of the biopharmaceutical company's stock worth $1,178,000 after purchasing an additional 14,947 shares during the period. Castellan Group boosted its stake in Halozyme Therapeutics by 4.5% in the 3rd quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company's stock worth $6,514,000 after purchasing an additional 4,876 shares during the period. Finally, Retirement Systems of Alabama boosted its stake in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock worth $22,282,000 after purchasing an additional 74,173 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HALO shares. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Benchmark reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $62.89.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. This trade represents a 5.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares of the company's stock, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,697 shares of company stock valued at $1,558,052 in the last three months. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO traded down $0.32 during trading on Wednesday, hitting $60.50. The stock had a trading volume of 373,872 shares, compared to its average volume of 1,434,146. The company has a 50 day simple moving average of $60.63 and a 200-day simple moving average of $55.24. Halozyme Therapeutics, Inc. has a 12 month low of $37.97 and a 12 month high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The firm has a market cap of $7.47 billion, a PE ratio of 17.64, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.